Summary: Admission to clinical trials is often based on the assumption of homogeneity of the population. A·group of 60 patients, all with pain in the neck or shoulder of at least 3 months duration, were studied. Expectation was graded before treatments were started by sharing out 100 points between freedom from side effects, pain relief, depression relief, improved mobility, improved sleep and speed of action. A double-blind crossover study of two established anti-inflammatory analgesics and placebo was carried out. Using analogue scales, patients were asked to grade their response. Side effects were recorded, and preference was established at the end of the study.
Introduction
In many medical specialties clinical trials have the drawback of being less than objective. In rheumatology there is an absence of entirely objective measurements. A measure such as ring size can be varied by the use of rubber gloves. Morning stiffness and grip strength, perhaps the two most accurate measures, are subjective. Often a decision with regard to the benefit of one therapy over another is based on the assumption that because a drug is preferred it is necessarily more effective. There may be other reasons for preference, e.g. fewer side effects or attractively coloured tablets.
Much reliance has been put on charges in pain. Recently, the visual analogue scale was introduced as a means of accurately estimating this (Berry & Huskisson 1972) , and in this study attempts have been made to use visual analogue scales to assess other factors that might affect preference. At the outset, patients were invited to grade in order of importance what they expected to gain from treatment. Then, during the course of a three-way clinical trial, these same factors were assessed at the end of each drug period. Patient preference was established at trial end. Attempts have been made in this study to determine whether patient expectation and patient response correlated with patient preference. crossover double-blind controlled study. Only patients with chronic pain (i.e. greater than three months) due to disorders of the neck and of the shoulder were included. The three drugs chosen were two known anti-inflammatory analgesic agents, azapropazone 300 mg three times a day, and naproxen 250 mg three times a day, and placebo, and each treatment period lasted 1 week. The double dummy technique was used. Exclusions included cancer, infection and the possibility of pregnancy, but all other conditions were included. Thus a heterogeneous population was deliberately chosen in whom the main presenting complaint was chronic pain.
Methods

Entry to trial-analysis ofexpectation from therapy
Before the first drug period, and following adequate explanation, patients were asked to share out 100 points among the following six factors, allotting points according to their expectations from treatment: freedom from side effects; pain relief; depression relief; increased mobility; sleep; speed of action. Patients were given the following definitions: 'relief of pain' and 'relief of depression' mean 'making pain less bad' and 'making feelings of sadness less bad'. 'Increasing mobility' means 'getting more able to move about'. Thus for each patient an initial expectation was obtained.
Course ofthe trial
At the start of treatment and at the end of each treatment period, the patients were asked to grade the following using a visual analogue scale within the stated limits: 0) Pain ('worst ever' and 'best ever'). (2) Pain relief ('none' and 'complete') . (3) Depression ('very depressed' and 'not depressed'). (4) Mobility ('immobile' and 'full mobility'). (5) Length of sleep ('longest' and 'shortest'). (6) Depth of sleep ('deepest ever' and 'lightest ever'). (7) Speed of efficacy ('slow, more than an hour' and 'instant'). (8) Trouble from capsules and tablets ('very annoying' and 'none'). Pain was also scored on a 4-point scale. Side effects were listed by means of a simple non-leading question. The trial was randomized for order. Patient preference was elicited in the usual way, preference order ofthe three drug periods being asked for at the end ofthe trial. At the end of each of the three treatment periods a venous blood sample was taken for measurement of the plasma concentration of drug.
Results
The patients' expectations of results of the treatment varied surprisingly. Pain relief and improvement of mobility were given the most emphasis by a majority, but 11 patients wanted lack of trouble from drugs more than any alternative. The mean scoring of all 60 patients is shown in Table 1 . Six patients dropped out of the trial and determination of blood concentration of the drugs at the end of each drug period showed 2 patients to have taken neither active drug throughout the trial. Patient preference is shown in Table 2 . Two patients were unable to state a preference and the preferences of the remaining 50 are given. Pain, as measured on the 4-point scale, was significantly lower during the naproxen week than during the placebo week (P<0.05) ( Table 3 ). Depression improved significantly during the azapropazone week compared to the placebo week (P < 0.05) (Table 4) . Table 5 shows the relationship between patients' preferences for the drugs and the other measures of response. No measure of response showed significant differences for patients reporting preferences for either drug. An exhaustive attempt was made to relate patients' initial expectations of therapy to their pretreatment condition as assessed by the measuring instruments described. Patients with high expectations of pain relief had less problems with mobility and less troubles with sleep than those who indicated lower expectations of pain relief (P<0.05 for both). Conversely, patients having high expectations of relief of depression had more problems with mobility than those with low expectations (P < 0.05 for both). Perhaps not surprisingly, patients having a higher expectation of sleep improvement had poor length and depth of sleep scores before treatment. There was a group of patients who gave high expectation marks to mobility, and a patient in this group was extremely likely to prefer a drug to placebo -72.2% of these patients preferred azapropazone to placebo and 82.4% preferred naproxen to placebo. These patients were looked at in more detail. The amount of pain was significantly reduced on azapropazone compared to placebo (58.3 mean score on azapropazone versus 45.8 on placebo, P<0.05, n= 18). Pain score was also significantly different (mean 1.50 on azapropazone versus 1.89 on placebo, P<0.05, n= 18). Mean pain score was 1.47 on naproxen and 1.94 on placebo (P < 0.05, n = 17). Side effectsoftherapy Side effects experienced in the trial are shown in Table 6 . One patient developed nausea and headache, and one dizziness while on naproxen and these preferred to leave the trial, while one patient experiencing anorexia and drowsiness on placebo also left. The 2 other side effects on azapropazone were depression and increase in girth, possibly due to fluid retention. This short-term study therefore suggests that side effects on these two drugs are relatively uncommon and occur at the same frequency on placebo. Eight patients allotted 30 or more of their 100 points to freedom from side effects and 5 of these experienced some symptom they attributed to one or more of the treatments, contributing seven ofthe total recorded. Thus they showed exactly the same incidence as their fellow patients. 
Discussion
This study has confirmed that choosing a heterogeneous population will not produce a homogeneous preference. It has been sensitive enough to demonstrate that naproxen and azapropazone are drugs that are both capable of producing pain relief and increasing mobility.
Patients have been demonstrated to prefer one drug to another for differing reasons, particularly if they started off with different expectations. There seems to have been a group who started off with an expectation of improving mobility and pain relief who derived just that benefit from drug and not placebo and when they did so they preferred the drug regardless of side effects. There was another group who although sufficiently in pain to seek medical attention nevertheless rated pain relief as a low priority. These patients have often considered sleep or relief of depression to be of more importance than relief of pain. In those patients we were unable to show pain relief as a dominant feature. These patients did, however, show improvement in their depressive state and this correlated with their preference for that drug. In our view it is important to select patients who are in need of a dominant property of a drug to take part in a study of that property, and this could be achieved by means of an expectation scale. Patients should not be included in a trial of pain when their major concern is insomnia or depression. This study was carried out in a rheumatological population; it would be relevant to do similar studies in other specialties. Attempts could also be made to use this concept of preselection for appropriate therapy as a means of more accurate definition of a patient's individual problem and so use drugs more effectively: this applies both in hospital and general practice.
